Summary Transition Therapeutics Inc (Transition) a subsidiary of OPKO Health Inc, is a biopharmaceutical company that develops medicines for the treatment of CNS disorders, Alzheimer’s disease and diabetes.The company develops drugs for the treatment of aggression associated with Down syndrome and Alzheimer’s disease.
It also develops a metabolic drug candidate for the treatment of type 2 diabetes and accompanying obesity.Transition is also currently conducting clinical trials on several upcoming drugs for the treatment of various diseases.
It partners with various other biopharmaceutical companies to market its products. Transition is headquartered in Toronto, Ontario, Canada.
Transition Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings.The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period.
The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope - Financial Deals - Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. - Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. - Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector. - Major Deals - Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios. - Business Description - A brief description of the company’s operations. - Key Employees - A list of the key executives of the company. - Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company. - Key Competitors - A list of the key competitors of the company. - Key Recent Developments - A brief on recent news about the company.
Reasons to Buy Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements - The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy - The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Our reports have been used by over 10K customers, including:
This study ’s Healthcare and Life Sciences team provides critical insights into the US COVID-19 vaccines and therapeutics market, including developing vaccines, supply chain considerations, and requirements to manage distribution. The study also identifies actionable and profitable growth opportunities for industry participants.
N Sulphoglucosamine Sulphohydrolase - Drugs In Development, 2021 Summary According to the recently published report ’N Sulphoglucosamine Sulphohydrolase - Drugs In Development, 2021’; N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 126.96.36.199) pipeline...
Tyrosine Protein Kinase Mer - Drugs In Development, 2021 Summary According to the recently published report ’Tyrosine Protein Kinase Mer - Drugs In Development, 2021’; Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 188.8.131.52) pipeline Target constitutes...
Aryl Hydrocarbon Receptor - Drugs In Development, 2021 Summary According to the recently published report ’Aryl Hydrocarbon Receptor - Drugs In Development, 2021’; Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) pipeline Target constitutes close to 29 molecules....
Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Drugs In Development, 2021 Summary According to the recently published report ’Neuropeptide Y Receptor Type 2 - Drugs In Development, 2021’; Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) pipeline Target constitutes close to 5...
Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 184.108.40.206) - Drugs in Development, 2021 Summary Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 220.127.116.11) pipeline Target constitutes close to 7 molecules. Out of which approximately 6 molecules are developed...
120 pages •
By Infiniti Research Limited
• May 2021
Global Microbiomes Market 2021-2025 The analyst has been monitoring the microbiomes market and it is poised to grow by $ 713.01 million during 2021-2025, progressing at a CAGR of over 24% during the forecast period. Our report on microbiomes market provides a holistic analysis, market size and forecast, trends, growth drivers,...
Microbiome - Targeted Therapeutics in Immunology - Thematic Research
The microbiome is considered the genetic material of all microorganisms existing in and on the human body.Large resident microbial communities exist in the gastrointestinal (GI) tract, skin, and respiratory tract, and...
The Alzheimer’s disease diagnostics and therapeutics market was valued at USD 6,632.82 million in 2020, and it is expected to reach approximately USD 9,073 million in 2026, registering a CAGR of nearly 5.36% during the forecast period, 2021-2026. The study titled, "Alzheimer’s and Parkinson’s diseases predict different COVID-19 outcomes, a...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.